1. Introduction {#sec1}
===============

There is no consensus regarding the choice of a gastrointestinal continuity restoration method following a subtotal gastrectomy for gastric cancer [@bib1]. When feasible, a Billroth I reconstruction method is commonly performed because it is technically simple. However, bile reflux develops in 8.4--56.3% of gastric cancer patients who undergo this procedure [@bib1], [@bib2], [@bib3]. Subsequently, severe gastritis and esophagitis are also reported after a Billroth I operation [@bib4], [@bib5]. Conversely, the incidence of bile reflux and reflux remnant gastritis at 12 months following surgery with a Roux-en-Y gastrointestinal reconstruction method is only 8--16% [@bib6], [@bib7]. However, Roux stasis syndrome occurs in 10--30% of patients [@bib8], [@bib9]. There is a lack of data on side effects and quality of life after the Balfour method for gastrointestinal continuity restoration.

We aimed to evaluate the impact on the global quality of life (QoL) status after the Billroth I, Balfour, and Roux-en-Y gastrointestinal continuity restoration methods following a subtotal gastrectomy in gastric cancer patients. These surgeries were performed as standard procedures at the National Institute of Oncology of Vilnius University, Lithuania. The decision on which reconstruction method was performed was made by a surgeon.

2. Material and methods {#sec2}
=======================

The Lithuanian version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) was used to assess the QoL in this retrospective cross-sectional case series study [@bib10]. The EORTC-QLQ-C30 was sent to 266 gastric cancer patients for self-completion. All the patients had undergone a R0 subtotal gastrectomy for gastric cancer from July 2007 to July 2012. The study participants were informed of the objectives of this questionnaire and confidentiality policy.

QoL data from the 153 patients who responded to the questionnaires following a subtotal gastrectomy for gastric cancer were obtained and evaluated. A list of questionnaire responders was stratified into three arms named based on the gastrointestinal continuity restoration method performed -- Billroth I (37 cases), Balfour (101 cases), and Roux-en-Y (15 cases) ([Fig. 1](#fig1){ref-type="fig"}). The mean scores with standard deviations of global health status, functional and symptom scales were compared between these three arms. The mean time after operation was 2.5 years with a range of 0.5--5 years.

The main characteristics of the enrolled patients as well as the peculiarities of the gastric cancer and its management are shown in [Table 1](#tbl1){ref-type="table"}. The sex, median age, cancer stage, and treatment modes in the three arms were similar. None of the patients had distant metastatic cancer at the time of surgery or questionnaire. A subtotal gastrectomy was generally performed with a conventional D1 or D2 lymphadenectomy [@bib11]. The size of the remnant stomach was independent of the type of gastric reconstruction and averaged 20% of the stomach. In the Billroth I reconstructions, the duodenum and remnant stomach were anastomosed using a hand-sewn method. When the Balfour modification was employed, an antecolic end-to-side gastrojejunostomy was performed on a long loop using a hand-sewn method. Braun\'s jejunojejunostomy was performed 20 cm below the gastrojejunostomy. The Roux-en-Y reconstruction of the gastrointestinal tract involved a division of the jejunum 20 cm distal to the Treitz ligament. The Roux limb was brought through the antecolic (nine patients) or retrocolic (six patients) route. An end-to-side gastrojejunostomy was anastomosed using a hand-sewn method. The continuity of the jejunum was subsequently reconstructed by hand-sewn jejunojejunostomy.

Statistical significance between the groups was analyzed by Student\'s t-test, an independent-samples T test, a one-way ANOVA, and Kruskal--Wallis H tests. All statistical analyses were performed using SPSS software, version 20.0.

3. Results {#sec3}
==========

[Table 2](#tbl2){ref-type="table"} shows the means and standard deviations of the global health status, functional and symptom scales of the Billroth I, Roux-Y and Balfour arms. The mean global health status scores for the patients following the Billroth I, Roux-en-Y, and Balfour reconstructive surgeries were 62 ± 20.09, 61 ± 24.08 and 56 ± 21.20, respectively, (p = 0.182). The mean scores of the functional scales were not lower than 60 in any of the patient groups. For most of the functional scales (i.e., physical, role, cognitive, and social), the mean of QoL score was best in the Billroth I and worst in the Roux-en-Y arms. Of eight postoperative symptoms, no statistically significant differences between the arms were found.

Comparisons of the global QoL, functional activities, and majority of the postgastrectomy symptom scores at different time points after surgery (≤1 year vs \> 1 year) did not reveal major significant differences between the groups. [Fig. 2](#fig2){ref-type="fig"} shows the mean values of the functional scales after 6--12 months and \>1 year. [Fig. 2](#fig2){ref-type="fig"} also shows that the patients scored better following the Roux-en-Y and Balfour gastrointestinal continuity restoration compared to the Billroth I surgery after 6--12 months. However, after more than one year, the functional scales scores were compared between the patient groups, and the QoL was better following the Billroth I and Balfour procedures.

The mean values of the symptom scores in the Billroth I, Balfour, and Roux-en-Y gastrointestinal continuity restoration arms after 6--12 months and \>1 year after surgery are shown in [Fig. 3](#fig3){ref-type="fig"}. The lower symptom scores reflect a better condition. [Fig. 3](#fig3){ref-type="fig"} highlights the trends and ranks of the gastrointestinal continuity restoration methods over the time. The first 6--12 months after surgery, the rank is (in descending order): Roux-en-Y, Balfour, and Billroth I. After 1 year the ranking is (in descending order): Billroth I, Balfour, and Roux-en-Y.

4. Discussion {#sec4}
=============

Health-related quality of life is becoming an important component of outcomes in cancer therapy [@bib12]. It is well known that patients who survive gastric cancer surgery may suffer from various nutritional and functional symptoms. We used the EORTC QLQ-C30 to assess the impact of the gastrointestinal reconstruction method on the global quality of life after a subtotal gastrectomy in gastric cancer patients.

The results of our study show that the patients\' global QoL status was not significantly affected by the gastrointestinal continuity restoration method used -- Billroth I, Roux-en-Y, or Balfour -- following a subtotal gastrectomy for gastric cancer. This finding corresponds to findings of other investigators who demonstrated that there is no statistically significant difference in the QoL between the Roux-en-Y, Billroth I, and Billroth II groups [@bib1], [@bib13]. Conversely, there are data showing that the Roux-en-Y reconstruction gives better clinical outcomes and QoL than the Billroth I procedure because it reduces the occurrence of reflux esophagitis and diarrhea [@bib14], [@bib15]. Our study augments this claim because it includes an evaluation of the Balfour procedure on the QoL, which resulted in several findings.

First, the physical functioning, cognitive and social QoL scales of the patients were better following the Billroth I procedure. Second, most of the functional activity scores favored the Balfour gastrointestinal continuity restoration method compared to the Roux-en-Y method, despite the fact that the global QoL score was higher in the Roux-en-Y surgery arm, which was quite difficult to interpret. However, the severity of postoperative symptoms was higher in the Roux-en-Y surgery arm compared with the Balfour surgery arm 1 year after surgery ([Fig. 3](#fig3){ref-type="fig"}). The lower severity of postoperative symptoms in the Roux-en-Y surgery arm compared to the Balfour surgery arm 6--12 months after the operation was very likely the key factor that influenced the higher global QoL score for the Roux-en-Y surgery. Thus, this finding is a good starting point for a further prospective comparative study in which the Roux-en-Y can be compared with the Balfour modification in two homogeneous gastric cancer patient cohorts. Third, while evaluating the impact of time (≤1 year *vs* \> 1 year) after each gastrointestinal restoration procedure on the QoL, the long-terms effects on the QoL for the patients more than one year after surgery were better following the Billroth I and Balfour procedures compared with the Roux-en-Y surgery.

These results supplement findings of other investigators who showed that, after a gastrectomy, gastric cancer patients generally suffer more from postgastrectomy symptoms during the first few months [@bib16], [@bib17], [@bib18]. One important factor in the disparity in the QoL is the difference in postgastrectomy symptoms between the 5-year survival and healthy population [@bib19].

5. Conclusion {#sec5}
=============

Our study demonstrates that the type of gastrointestinal continuity restoration method does not significantly affect a patient\'s QoL after surgery. This means that both the Balfour and Roux-en-Y methods may be equally and broadly suitable in practise. The application of the Billroth I procedure is limited in gastric cancer surgery. Nevertheless, we have to conclude that the best global QoL score was obtained after the Billroth I surgery. Furthermore, an assessment of the values of the functional activity and symptom scales revealed that the Roux-en-Y modification is better than the Balfour gastrointestinal continuity restoration method in five functional categories and seven of eight postoperative symptom categories 6--12 months after surgery. On the contrary, the same methodological assessment of the values from both scales has shown that the Balfour modification is better than the Roux-en-Y gastrointestinal continuity restoration method in four of five functional categories and in all eight postoperative symptom categories one year after surgery. Further well-designed prospective randomized trials comparing QoLs following the Roux-en-Y and Balfour surgeries are needed. Future trials should include the supplementary gastric cancer module QLQ-STO22 for a more detailed QoL assessment.
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###### 

The main characteristics of the enrolled patients as well as the peculiarities of the gastric cancer and its management in the Billroth I, Roux-Y and Balfour arms.

  Characteristics                   Billroth I, n = 37   Roux-en-Y, n = 15   Balfour, n = 101
  --------------------------------- -------------------- ------------------- ------------------
  Sex                                                                        
   Male                             17 (45.9%)           7 (46.7%)           51 (50.5%)
   Female                           20 (54.1%)           8 (53.3%)           50 (49.5%)
  Age median (standard deviation)   67 (±12)             62 (±13)            67 (±13)
  Depth of invasion                                                          
   T1                               15 (40.5%)           7 (46.7%)           39 (38.6%)
   T2                               8 (21.6%)            1 (6.7%)            33 (32.7%)
   T3                               13 (35.1%)           5 (33.3%)           27 (26.7%)
   T4                               1 (2.7%)             2 (13.3%)           2 (2.0%)
  Lymph node metastasis                                                      
   N0                               22 (59.5%)           11 (73.3%)          56 (55.4%)
   N1                               10 (2.7%)            0                   27 (26.7%)
   N2                               5 (13.5%)            1 (6.7%)            12 (11.9%)
   N3                               0                    3 (20%)             6 (5.9%)
  Stage                                                                      
   I                                18 (48.6%)           8 (53.3%)           53 (52.5%)
   II                               10 (27.0%)           3 (20%)             31 (30.7%)
   III                              9 (24.3%)            4 (26.7%)           17 (16.8%)
   IV                               0                    0                   0
  Lymphadenectomy                                                            
   D1                               0                    3 (20%)             0
   D2                               37 (100%)            12 (80%)            101 (100%)
  Adjuvant chemotherapy                                                      
   Yes                              13 (35.1%)           4 (26.7%)           31 (30.7%)
   No                               22 (64.9%)           11 (73.3%)          70 (69.3%)
  Time after surgery                                                         
   ≤1 year                          6 (16.2%)            3 (20%)             21 (20.8%)
   \>1 year                         31 (83.8%)           12 (80%)            80 (79.2%)

No significant differences found.

###### 

The means and standard deviations of the global health status, functional and symptom scales in the Billroth I, Roux-Y and Balfour arms.

  Scales                   Billroth I   Roux-en-Y    Balfour      p value\*\*
  ------------------------ ------------ ------------ ------------ -------------
  Global health status\*   62 ± 20.09   61 ± 24.08   56 ± 21.20   0.182
  Functional scales\*                                             
   Physical                71 ± 21.80   64 ± 31.35   69 ± 21.73   0.767
   Role                    70 ± 28.90   66 ± 35.34   72 ± 31.86   0.703
   Emotional               68 ± 26.97   71 ± 24.77   64 ± 26.30   0.533
   Cognitive               76 ± 20.99   69 ± 36.11   72 ± 27.56   0.918
   Social                  72 ± 30.44   61 ± 38.14   70 ± 31.60   0.688
  Symptom scales\*                                                
   Fatigue                 50 ± 30.39   43 ± 27.37   49 ± 27.91   0.765
   Nausea and vomiting     18 ± 22.20   14 ± 35.00   13 ± 21.25   0.134
   Pain                    28 ± 28.02   38 ± 36.99   34 ± 29.32   0.534
   Dyspnea                 20 ± 29.88   22 ± 34.88   21 ± 31.57   0.999
   Insomnia                50 ± 32.03   56 ± 37.09   49 ± 33.53   0.771
   Appetite loss           28 ± 33.81   40 ± 38.21   23 ± 28.18   0.225
   Constipation            26 ± 31.98   22 ± 37.09   19 ± 29.68   0.433
   Diarrhea                28 ± 31.37   24 ± 26.62   25 ± 30.10   0.890

\* a higher score denotes a better quality of life, either global or functional; higher scores for the symptom scales show problems which negatively influence quality of life; \*\*p value was calculated using Kruskal--Wallis H test.
